Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions

Qin Qin, Baosheng LiJournal of Cancer Research and Therapeutics 2019 15(4):743-750 The development of inhibitors of immune checkpoints has revolutionized the treatment for a subset of patients with advanced nonsmall cell lung cancer (NSCLC), resulting in promising clinical outcomes and durable responses. Pembrolizumab, a humanized anti-programmed cell death-1 (PD-1) antibody, has been approved as a first-line treatment for patients with advanced NSCLC with PD-L1 expression of ≥50% and as a second-line treatment for PD-L1 expression of ≥1%. Pembrolizumab in combination with standard chemotherapy has shown better clinical outcomes than chemotherapy as a first-line therapy in patients with advanced NSCLC without targetable mutations, regardless of PD-L1 expression. In this review, we summarized the current indications of pembrolizumab for NSCLC, briefly described immune-relevant pneumonitis and discussed potential biomarkers to predict clinical efficacy.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

AbstractBackgroundAnti-programmed cell death receptor (PD)-1 antibody treatment results in better prognosis than standard chemotherapy in patients with non-small cell lung cancer (NSCLC), especially those with high PD-ligand 1 (PD-L1) expression. However, several studies have reported a lack of antitumor effect of PD-1 antibody, even in patients with high PD-L1 expression. Therefore, reliable predictors of treatment response are urgently needed. The albumin –globulin ratio (AGR) is associated with prognosis in several cancers. We aimed to determine whether AGR is a predictive biomarker of anti-PD-1 antibody response ...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThese results indicate that the SNP538(G  >  A) in theABCC11 gene is a potential determinant for S-1 treatment.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
BRAF gene mutation is found in about 2%-4% of the patients with non-small cell lung cancer (NSCLC). This type of NSCLC is characterized by high malignancy, low efficacy of chemotherapy and poor prognosis. Although the combination treatment of BRAF inhibitor and MEK inhibitor has achieved remarkable results in advanced NSCLC patients with BRAF V600E mutation, which has been written into the National Comprehensive Cancer Network (NCCN) guidelines, severe side effects of the combination therapy are frequently observed. There isn ’t effective treatment strategy after drug resistance, and targeted therapy for non-V600E mu...
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Since the development of immune checkpoint inhibitors targeting the programmed cell death 1 –programmed cell death-ligand 1 (PD-1–PD-L1) axis, therapeutic advances have been achieved in non-small cell lung cancer (NSCLC) [1–5]. In advanced NSCLC, combination therapy of immune checkpoint inhibitors and platinum-based chemotherapy has yielded improved overall survival compared with pla tinum-based chemotherapy alone [6–8]. These immune checkpoint inhibitors are believed to prevent PD-1-positive cytotoxic T lymphocytes (CTLs) from lapsing into exhaustion via interplay with PD-L1-positive tumor cells an...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Authors: Ren H, Hu Y, Xie T, Jin C, Hu Y, Yang B Abstract Changes of epidermal growth factor receptor (EGFR) and cytokeratin fragment antigen 21-1 (CYFRA21-1) in patients with advanced non-small cell lung cancer (NSCLC) before and after gefitinib treatment were observed to explore the significance of such changes. A total of 175 patients with advanced NSCLC who were admitted to Hubei Cancer Hospital from July 2012 to October 2015 were collected and divided into two groups: the control group (85 patients who received conventional chemotherapy) and the experimental group (90 patients treated with gefitinib combined w...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Hong W, Wu Q, Zhang J, Zhou Y Abstract Previous studies have demonstrated a significant difference in clinical characteristics between patients with non-small cell lung cancer (NSCLC) harboring exon 19 deletion (19-del) and an exon point mutation (21-L858R) in EGFR. The present retrospective study aimed to investigate the differential prognosis in patients with NSCLC harboring exon 19-del and 21-L858R mutations. The clinical and follow-up data of 137 patients treated at the Zhongnan Hospital of Wuhan University (Wuhan, Hubei, China) between August 2012 and August 2016, who were diagnosed with stage IIIB-IV...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Rossi A Abstract Introduction: Nonsquamous non-small-cell lung cancer (NSCLC) is divided in oncogene-addicted subgroups, highly expressed programmed death ligand-1 (PD-L1 ≥ 50%) subgroup, and "negative" subgroup. The latter represents the most common group comprising about 50% of all new diagnoses of nonsquamous NSCLC. For this group, chemotherapy was the standard approach with pemetrexed- and/or bevacizumab-based regimens reaching an overall survival of about 12-17 months. Areas covered: This review will focus on the new options for combination therapies, which have already recently arrived o...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
Immunotherapy with PD-1/PDL-1 checkpoint inhibitors is transforming the landscape in advanced non-small cell lung cancer, prolonging survival to unprecedented lengths compared with chemotherapy alone.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and unique subtype of primary non-small cell lung cancer (NSCLC) that histologically resembles undifferentiated nasopharyngeal carcinoma (NPC) [1]. It is recognized to be etiologically associated with Epstein-Barr virus (EBV) infection in endemic area [2]. Currently, pulmonary LELC is classified as “other and unclassified carcinomas” according to the 2015 World Health Organization Classification Lung Tumors [3]. Over the past decades, less than 600 cases have been reported in the literature.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer